[go: up one dir, main page]

NO20075804L - Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel - Google Patents

Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel

Info

Publication number
NO20075804L
NO20075804L NO20075804A NO20075804A NO20075804L NO 20075804 L NO20075804 L NO 20075804L NO 20075804 A NO20075804 A NO 20075804A NO 20075804 A NO20075804 A NO 20075804A NO 20075804 L NO20075804 L NO 20075804L
Authority
NO
Norway
Prior art keywords
indazole derivative
retinal neuronal
retinal
nerve cell
agent
Prior art date
Application number
NO20075804A
Other languages
English (en)
Inventor
Atsushi Shimazaki
Hisayuki Seike
Takeshi Matsugi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of NO20075804L publication Critical patent/NO20075804L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Som et resultat av intense studier for formålet å finne en ny medisinsk anvendelse av et indazolderivat, ble det funnet at et indazolderivat inhiberer glutamat-indusert retinal neuronal celledød hos rottefoster retinale neuronale celler, med andre ord virker indazolderivatet direkte på de retinale neuronale celler og fremviser en effekt med å beskytte retinale neuronale celler. Følgelig er indazolderivatet anvendelig for hindring eller behandling av en øyesykdom assosiert med retinal neuronal celleskade eller retinal skade.
NO20075804A 2005-04-13 2007-11-12 Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel NO20075804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005116141 2005-04-13
PCT/JP2006/307715 WO2006112313A1 (ja) 2005-04-13 2006-04-12 インダゾール誘導体を有効成分として含む網膜神経細胞保護剤

Publications (1)

Publication Number Publication Date
NO20075804L true NO20075804L (no) 2008-01-09

Family

ID=37115037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075804A NO20075804L (no) 2005-04-13 2007-11-12 Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel

Country Status (9)

Country Link
US (1) US8252945B2 (no)
EP (1) EP1870099A4 (no)
JP (1) JPWO2006112313A1 (no)
KR (1) KR20070119726A (no)
CN (1) CN101160128B (no)
CA (1) CA2604956A1 (no)
NO (1) NO20075804L (no)
RU (1) RU2392938C2 (no)
WO (1) WO2006112313A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
JP2012515164A (ja) 2009-01-09 2012-07-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜障害を処置するための治療組成物
TW201202214A (en) * 2010-05-27 2012-01-16 Santen Pharmaceutical Co Ltd Novel indazole derivative or salt thereof, production intermediate thereof, and prophylactic or therapeutic agent for chorioretinal degeneratire disease using the same
TWI476188B (zh) * 2010-05-27 2015-03-11 Ube Industries 新穎吲唑衍生物或其鹽及其製造中間體、以及使用其之抗氧化劑
JP2013530250A (ja) 2010-07-13 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二環式ピリミジン化合物
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2651949B1 (en) 2010-12-16 2015-07-15 Bayer Intellectual Property GmbH Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
US10347667B2 (en) * 2017-07-26 2019-07-09 International Business Machines Corporation Thin-film negative differential resistance and neuronal circuit
US20230322749A1 (en) * 2020-06-19 2023-10-12 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4822820A (en) 1986-11-24 1989-04-18 Alcon Laboratories, Inc. Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
ATE101342T1 (de) 1988-09-06 1994-02-15 Kabi Pharmacia Ab Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
RU2073518C1 (ru) * 1993-06-17 1997-02-20 Совместное русско-американское акционерное общество закрытого типа "Неофарм" Средство, восстанавливающее функцию сетчатой оболочки глаза
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP3625946B2 (ja) 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
TW420611B (en) 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
JP4004109B2 (ja) 1996-09-17 2007-11-07 参天製薬株式会社 含フッ素プロスタグランジン誘導体および医薬
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JPH10259179A (ja) 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
JP4372905B2 (ja) 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
EP1252895A4 (en) 2000-01-31 2003-04-16 Santen Pharmaceutical Co Ltd REMEDIES FOR OPHTHALMIC DISORDERS
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AR030275A1 (es) 2000-03-24 2003-08-20 Sucampo Pharmaceuticals Inc Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla
CN1243548C (zh) 2000-09-13 2006-03-01 参天制药株式会社 滴眼液
JP2002293771A (ja) 2001-03-30 2002-10-09 Asahi Glass Co Ltd 新規なエーテル型ジフルオロプロスタグランジン誘導体またはその塩
EP1378247B1 (en) 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EP1410808A4 (en) 2001-07-02 2009-07-29 Santen Pharmaceutical Co Ltd MEDIUM FOR THE PROTECTION OF THE SEHNERV WITH ALPHA 1 RECEPTOR BLOCKER AS AN ACTIVE SUBSTANCE
JP2003146904A (ja) 2001-11-08 2003-05-21 Nippon Shinyaku Co Ltd 緑内障治療薬
JP2003321442A (ja) 2002-04-24 2003-11-11 Santen Pharmaceut Co Ltd 新規なジフルオロプロスタグランジンアミド誘導体
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
ES2426288T3 (es) * 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol

Also Published As

Publication number Publication date
RU2392938C2 (ru) 2010-06-27
JPWO2006112313A1 (ja) 2008-12-11
RU2007141887A (ru) 2009-05-20
CN101160128B (zh) 2010-08-18
CA2604956A1 (en) 2006-10-26
US20090012123A1 (en) 2009-01-08
CN101160128A (zh) 2008-04-09
EP1870099A1 (en) 2007-12-26
WO2006112313A1 (ja) 2006-10-26
EP1870099A4 (en) 2008-07-16
KR20070119726A (ko) 2007-12-20
US8252945B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
NO20075804L (no) Beskyttende middel for retinal nervecelle omfattende indazolderivat som aktivt middel
NO20075464L (no) Protektivt middel for retinal nervecelle som inneholder prostaglandin F2alfaderivat som aktiv ingrediens
Masiello Animal models of type 2 diabetes with reduced pancreatic β-cell mass
NO20072170L (no) Oftalmiske sammensetninger og fremgangsmater for behandling av oyne
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
NO20050550L (no) Vevsbeskyttende cytokiner for beskyttelse, gjennoppbygging og oking av responsive celler, vev og organer
NO20075149L (no) Fremgangsmate til a redusere mikrobiell kontaminasjon
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
PL1682126T3 (pl) Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
BRPI0710085B8 (pt) composições oftálmicas e seus kits
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AR062046A1 (es) Soluciones oftalmicas
ATE406881T1 (de) Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
NO20034094D0 (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
WO2008070132A3 (en) Methods of use of trk receptor modulators
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
WO2007105203A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
NO20074850L (no) Oftalmologiske sammensetninger og anvendelse derav
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
CA2634419C (en) Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
BRPI0510037A (pt) dispensador

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application